CD40 and neoplasm: This offers a plausible explanation for the disjuncture between our in vitro and in vivo T cell activation data, which has also been documented by Hu-Lieskovan and colleagues25, and further supports the complementarity of MEK inhibitors and agonist anti-CD40 Ab in tumor therapy.